Skip to main content

Kronos Bio, Inc. (KRON)

NASDAQ: KRON · IEX Real-Time Price · USD
24.09 0.14 (0.58%)
Sep 24, 2021 11:20 AM EDT - Market open
Market Cap1.35B
Revenue (ttm)n/a
Net Income (ttm)-128.01M
Shares Out56.25M
EPS (ttm)-3.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,543
Open23.89
Previous Close23.95
Day's Range23.18 - 24.15
52-Week Range18.02 - 39.60
Betan/a
AnalystsBuy
Price Target42.25 (+75.4%)
Est. Earnings DateNov 11, 2021

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy...

IndustryBiotechnology
IPO DateOct 9, 2020
Employees90
Stock ExchangeNASDAQ
Ticker SymbolKRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Kronos Bio stock is "Buy." The 12-month stock price forecast is 42.25, which is an increase of 75.38% from the latest price.

Price Target
$42.25
(75.38% upside)
Analyst Consensus: Buy

News

Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

1 month ago - GlobeNewsWire

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of P...

Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients

1 month ago - GlobeNewsWire

Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials...

3 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

4 months ago - GlobeNewsWire

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Grow...

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

5 months ago - GlobeNewsWire

Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the...

5 months ago - GlobeNewsWire

Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the...

5 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia

6 months ago - GlobeNewsWire

Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor T...

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

6 months ago - GlobeNewsWire

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute...

Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval

6 months ago - GlobeNewsWire

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC...

KB-0742 generated using the company's proprietary small molecule microarray (SMM) screening platform

6 months ago - GlobeNewsWire

Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced part...

7 months ago - GlobeNewsWire

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the ...

7 months ago - GlobeNewsWire

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor ...

MYC amplification found in approximately 30% of solid tumors

9 months ago - GlobeNewsWire

Kronos Bio Announces Participation in Upcoming Investor Conferences

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced tha...

10 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia

10 months ago - GlobeNewsWire

Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

10 months ago - GlobeNewsWire

U.S. IPO Week Ahead: Hot IPO Market Takes A Break For Election Week

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...

10 months ago - Seeking Alpha

Last Week's Notable Insider Buys: Carnival, Citigroup And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other symbols:CCLBAMFUBOHEISTTK
11 months ago - Benzinga

Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additio...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel ...

11 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other symbols:FUBOINTZSPRBSTTK
11 months ago - Seeking Alpha

Kronos Bio's stock opens TK% above IPO price

Shares of Kronos Bio Inc. soared in their public debut, as they opened 50% above the initial public offering price. The stock's first trade was at $28.50 at 11:58 a.m.

11 months ago - Market Watch

FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs

This week has down with 6 IPOS scheduled for Thursday and Friday. FuboTV: Sport first live tv streaming company Fubo TV (OTC: FUBO) is uplisting to the Nasdaq.

Other symbols:FUBO
11 months ago - Benzinga

Kronos Bio prices upsized IPO above range at $19 a share

Kronos Bio Inc. priced its upsized initial public offering at $19 a share, above its $16 to $18 price range. The California-based biotech sold 13.2 million shares to raise about $250.8 million.

11 months ago - Market Watch

Kronos Bio Announces Pricing of Initial Public Offering

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeu...

11 months ago - GlobeNewsWire